Archive for November, 2012

Cell therapy industry 2027: Increased transparency – a major opportunity or transient fad?

Author: David Brindley, 11/30/12

The global health care sector is innovative, impactful and, despite addressing fundamental problems in human health, can be inescapably faddish. Despite the industry’s pride in an empirical approach that yields robust and practicable data, the covers of Nature, Science and Cell can be as ephemeral as those of Vogue and Tatler. The latest in vogue…Read more

Male infertility: Stem cells to the rescue?

Author: Angela C. H. McDonald, 11/27/12

Last month, I blogged about recent stem cell advances toward a solution for female infertility. While this post may have left you excited about the potential for stem cells to help women with fertility complications start a family, it may also have left you wondering: “What about the other half?” After all, male infertility accounts…Read more

What if the game changes again? Perfect ES models in sight

Author: Paul Krzyzanowski, 11/21/12

  While the 2012 US election was in full swing, I reminded readers that despite the dominance of the world’s economic problems in this cycle, stem cell research was a political issue that hadn’t completely gone away.Methods to generate induced pluripotent stem cells (iPS cells) have constantly improved over the past few years, elegantly positioning…Read more

Creating an ecosystem for Canadian RM commercialization

Author: Michael May, 11/19/12

James Till and Ernest McCulloch identified stem cells 50 years ago in Toronto, and their legacy is a vibrant community of scientists who are leaders in this field of research. But what does that mean in terms of producing products and therapies to heal and cure patients? While Canada is an acknowledged leader in the…Read more

On nations and inflammation: How viruses can promote cellular reprogramming

Author: Holly Wobma, 11/14/12

As many of you well know, the U.S. presidential election recently came to a close. Over the last year, there have been numerous speeches from a variety of sources, some of which have been able to rally the masses, due not only to their content but also the speaker’s masterful elocution. Indeed, when it comes…Read more

The future of the stem cell controversy: Do citizens prefer iPS cells?

Author: Nick Dragojlovic, 11/08/12

If you’ve been feeling like you can’t open a web browser these days without finding a story about induced pluripotent stem cells (iPSCs), you’re not alone.  Unlike embryonic stem cells, iPSCs are created by directly reprogramming adult cells taken from donors or patients, and they’ve been all over the news. Most notably, Sir John B….Read more

Cell therapy industry 2027: Business models, best practices and big data

Author: David Brindley, 11/05/12

Recently, in the twilight on a balmy summer’s evening in DC, an irrationally passionate cell therapy war room convened over meze, ouzo and retsina. And considered the meaty question posed by Lonza’s Jon Rowley: “Where do you think you and the cell therapy industry will be in fifteen years?” I anticipate there will be three…Read more